| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,960 | 1,320 | 18:13 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | BioRestorative Therapies, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| BIORESTORATIVE THERAPIES Aktie jetzt für 0€ handeln | |||||
| Di | BioRestorative Therapies, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| Mo | BioRestorative Therapies, Inc: BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease | 1 | GlobeNewswire (USA) | ||
| 13.11. | BioRestorative Therapies GAAP EPS of -$0.33 misses by $0.03, revenue of $0.01M misses by $0.51M | 2 | Seeking Alpha | ||
| 13.11. | BioRestorative outlines BioCosmeceuticals expansion with new leadership and eyes $63B market opportunity | 1 | Seeking Alpha | ||
| 12.11. | Earnings Call Transkript: BioRestorative Therapies meldet deutlichen Umsatzrückgang für Q3 2025 | 1 | Investing.com Deutsch | ||
| 12.11. | BioRestorative Therapies, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11. | BioRestorative Therapies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.11. | Earnings Outlook For BioRestorative Therapies | 1 | Benzinga.com | ||
| 27.10. | BioRestorative Therapies, Inc: BioRestorative Awarded Notice of Allowance for Japanese Patent - Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market | 2 | GlobeNewswire (USA) | ||
| 22.10. | BioRestorative Therapies, Inc: BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio | 1 | GlobeNewswire (USA) | ||
| 15.10. | BioRestorative Therapies, Inc: BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit | 1 | GlobeNewswire (USA) | ||
| 08.10. | BioRestorative Therapies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.10. | BioRestorative Therapies, Inc: BioRestorative CEO Lance Alstodt Interviewed on "The Big Biz Show" | 3 | GlobeNewswire (USA) | ||
| 06.10. | BioRestorative Therapies: Aktie fällt nach Kapitalerhöhung über 1,1 Mio. Dollar | 2 | Investing.com Deutsch | ||
| 06.10. | BioRestorative Therapies stock falls after $1.1M registered offering | 1 | Investing.com | ||
| 06.10. | BioRestorative Therapies nimmt 1,085 Millionen US-Dollar über Aktienplatzierung ein | 4 | Investing.com Deutsch | ||
| 06.10. | BioRestorative Therapies raises $1.085 million in registered offering | 2 | Investing.com | ||
| 06.10. | BioRestorative Therapies, Inc: BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market | 111 | GlobeNewswire (Europe) | MELVILLE, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies... ► Artikel lesen | |
| 25.09. | BioRestorative Therapies: Aktionäre billigen Direktorenwahl und Aufstockung des Aktienplans | 1 | Investing.com Deutsch |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,40 | -1,76 % | BioNTech Aktie: Große Gewinne? - Bayer, Evotec, Hensoldt, Kontron und Rheinmetall im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| EVOTEC | 5,176 | +0,27 % | Eilmeldung am Abend: EVOTEC SE kurz vor Entscheidungsphase | ||
| MEDIGENE | 0,026 | -25,14 % | MEDIGENE AG stürzt ab - ich traue meinen Augen kaum! | ||
| CUREVAC | 4,510 | -0,57 % | HV-Termine: Hauptversammlungen bei artnet, BVB, Cherry, CureVac, Schloss Wachenheim, SDM, The Grounds | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,456 | +8,83 % | Patente, Potenzial, Übernahmekandidat? Geld verdienen mit weniger Risiko: Das Geheimnis von BioNxt Solutions | In der Hochrisikowelt der Biotechnologie ist der Weg vom Labor zum zugelassenen Medikament oft ein Martyrium. Das kanadische Unternehmen BioNxt Solutions könnte den Schlüssel für einen weniger schmerzhaften... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,502 | -3,09 % | Defence Therapeutics Inc.: Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology | Montreal, Quebec--(Newsfile Corp. - November 19, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation... ► Artikel lesen | |
| KUROS BIOSCIENCES | 29,200 | -0,68 % | Kuros erhöht nach den ersten neun Monaten das Umsatzziel | Schlieren - Das Medtechunternehmen Kuros zeigt sich nach den ersten neun Monaten zuversichtlicher betreffend der Umsatzentwicklung im Gesamtjahr 2025. Von Januar bis September erhöhte das Unternehmen... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,438 | -2,45 % | Breaking News: NurExone im Rennen um höchsten Biotech-Preis der Welt | ||
| EVONEXT | 0,924 | -2,33 % | Adhoc: EvoNext Holdings SA: EvoNext Holdings SA publishes half-year report 2025 | EvoNext Holdings SA / Key word(s): Half Year Results
EvoNext Holdings SA publishes half-year report 2025
21-Aug-2025 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art.... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 60,76 | -0,30 % | Halozyme Therapeutics, Inc.: Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery | Royalty revenue contribution expected to begin as early as 2030
Initial partner targets include derisked MoAs that are approved blockbusters today
Highly scalable... ► Artikel lesen | |
| IMMATICS | 9,050 | +1,00 % | Immatics Announces Third Quarter 2025 Financial Results and Business Update | Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,001 | -96,30 % | Revive Therapeutics Ltd.: Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement | TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing... ► Artikel lesen | |
| CYBIN | 5,150 | 0,00 % | Canaccord Genuity lowers Cybin stock price target to $45 on dilution | ||
| ARCADIA BIOSCIENCES | 2,530 | -100,00 % | Arcadia Biosciences, Inc.: Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights | -- Zola® year-to-date revenues increase 26% year over year ---- Arcadia gross profit margins exceed 30% for 11th straight quarter ---- Arcadia cash balance declines by only $257K to $1.1M -- DALLAS... ► Artikel lesen | |
| LAVA THERAPEUTICS | 1,510 | -4,43 % | LAVA Therapeutics N.V.: LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq | UTRECHT, The Netherlands, and PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ("LAVA") (Nasdaq: LVTX) today announced that 22,877,463 of LAVA's common shares, representing approximately... ► Artikel lesen |